Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA
Monogram Orthopaedics, Inc. (NASDAQ: MGRM) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Monogram Orthopaedics, Inc. (NASDAQ: MGRM) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $4.00 price target on the stock.
Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million
Monogram Technologies Reports Third Quarter 2024 Financial Results [Yahoo! Finance]